within Pharmacolibrary.Drugs.ATC.L;

model L04AF07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.991,
    Cl             = 6.833333333333332e-05,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.138,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 15.0,            
    Vdp             = 0.0849,
    k12             = 11.5,
    k21             = 11.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AF07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate-to-severe plaque psoriasis in adults. It is approved and commercially available in several countries for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after single and repeated oral administration.</p><h4>References</h4><ol><li><p>Truong, TM, Pathak, GN, Singal, A, Taranto, V, &amp; Rao, BK (2024). Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. <i>The Annals of pharmacotherapy</i> 58(4) 416–427. DOI:<a href=\"https://doi.org/10.1177/10600280231153863\">10.1177/10600280231153863</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37341177/\">https://pubmed.ncbi.nlm.nih.gov/37341177</a></p></li><li><p>Chimalakonda, A, Burke, J, Cheng, L, Catlett, I, Tagen, M, Zhao, Q, Patel, A, Shen, J, Girgis, IG, Banerjee, S, &amp; Throup, J (2021). Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. <i>Dermatology and therapy</i> 11(5) 1763–1776. DOI:<a href=\"https://doi.org/10.1007/s13555-021-00596-8\">10.1007/s13555-021-00596-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34471993/\">https://pubmed.ncbi.nlm.nih.gov/34471993</a></p></li><li><p>Eichinger, JM, Shan, DM, Greenzaid, JD, Anakwenze, L, &amp; Feldman, SR (2024). Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(4) 249–262. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2335310\">10.1080/17425255.2024.2335310</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38529623/\">https://pubmed.ncbi.nlm.nih.gov/38529623</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AF07;
